Real-World Evidence as an Early Radar for Label Expansion

Label expansion rarely follows a clean, linear path. In many therapeutic areas, clinical practice evolves faster than formal registration. Clinicians may prescribe a medicine in a population, line of therapy, dose, route, or indication that is not described in the Guideline on Summary of Product Characteristic (SmPC), particularly when there are limited on-label options or when the expected benefit–risk profile appears favorable for a specific patient group. This practice is commonly referred to as off-label use. Off-label use can be substantial and is legally permitted under conditions in the Netherlands, but it is heterogeneous and therefore not always straightforward to interpret from routine data.

For manufacturers, the key question is not whether off-label use exists, but whether an observed off-label pattern reflects:

• • documentation or coding artefact,

• • channel or reimbursement dynamics, or

• • a clinically coherent, outcomes-relevant signal worth advancing into an evidence-generation plan

Real-world evidence (RWE) can support this early “radar” function by identifying emerging use patterns, characterizing where and in whom they occur, and prioritizing which signals merit outcomes evaluation – especially to improve monitoring of effectiveness and side effects in clinical practice.

Off-label use isn’t evidence on its own – but it’s a useful place to look

Off-label flags in routine healthcare datasets require careful interpretation. They can reflect true use outside the registered indication, but they may also capture sub-indications recorded under broader authorized categories, combination-therapy “crosslink” records, or use of non-authorised products (e.g., compounded preparations or certain blood products).[1] That nuance matters: treating every off-label flag as “outside label” can create false positives, while ignoring off-label patterns can mean missing high-value opportunities.